Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent

Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent

Apr 25, 2013
|
Ben Butkus
Premium

Cepheid's Xpert CT/NG assay for the detection and differentiation of Chlamydia trachomatis and Neisseria gonorrhoeae, launched in the US at the start of the year, has seen the greatest uptake of any new Xpert test since Xpert MRSA, President and CEO John Bishop said recently.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Genomic NFT

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

ACMG's Gregg Resigns

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Interaction Prediction

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

PNAS Papers on TB in Tibet, Chemo-Induced Stress in Multiple Myeloma, Wasp Symbiont

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Featured Webinar

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In PCR

  1. LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

  2. OncoDiag Taking Aim at Broader Adoption of Molecular Multiplex Test for Bladder Cancer Recurrence

    Premium

  3. Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer

  4. Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

  5. FDA Issues EUAs for SARS-CoV-2 Tests From Synergy Diagnostic Laboratory, Celltrion

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.